Peptide Profile: MOTS-c is a small mitochondrial-derived peptide involved in regulating energy metabolism, improving insulin sensitivity, and enhancing glucose uptake in skeletal muscle. It acts through pathways such as AMPK to support metabolic homeostasis, potentially reducing obesity, insulin resistance, and inflammation while mimicking some exercise-induced effects. Though promising for metabolic health and aging, MOTS-c is still experimental and not FDA-approved for human clinical use. (PMC)

MOTS-c Dosing Protocol (Male & Female)

The following protocol is educational only and based on emerging research and anecdotal peptide therapy protocols. Clinical supervision is essential and MOTS-c is not FDA-approved. (peptidedosages.com)

Phase Timeframe Dose (Male) Dose (Female) Notes Monitoring
Baseline Assessment Week –2 to Day 0 N/A N/A Evaluate metabolic profile: fasting glucose/A1c, lipids, BMI, liver/kidney panels. Discuss goals (metabolic health, fat loss, endurance). Confirm no contraindications. Labs, clinical review; pregnancy test if applicable
Initiation Weeks 1–2 200 mcg daily SQ 200 mcg daily SQ Start at lowest practical dose to assess tolerability. Subcutaneous (SQ) injection using U-100 insulin syringe. Watch GI tolerance, injection site reactions
Early Titration Weeks 3–4 400 mcg daily SQ 400 mcg daily SQ Gradually increase every 2 weeks if tolerated. Typical frequency is once daily. Check fasting glucose, appetite changes
Incremental Increase Weeks 5–6 600 mcg daily SQ 600 mcg daily SQ Continue gradual escalation; adjust based on side effects and goals. Monitor energy, sleep, GI symptoms
Mid Protocol Weeks 7–8 800 mcg daily SQ 800 mcg daily SQ Approaching upper range used in research/anecdotal protocols. Re-check metabolic labs
Target Dose Phase Weeks 9–10+ 1,000 mcg (1 mg) daily SQ 1,000 mcg (1 mg) daily SQ Maintain effective dose for up to 12 weeks (may extend to 16 weeks). Stop escalation once goal achieved or side effects emerge. Periodic labs; adjust co-medications
Maintenance / Cycle End Week 12–16 Maintain chosen dose or taper Maintain chosen dose or taper Continue dose for desired period under clinician supervision. Some protocols cycle 8–12 weeks then pause. Clinical review; taper if needed

General Notes:
• MOTS-c dosing typically ranges from 200 mcg to 1,000 mcg daily with gradual titration. (peptidedosages.com)
• Protocols may split total weekly dose into multiple injections (e.g., several times per week). (American Medical Wellness)
• There is no standard sex-based dosing; adjustments are based on individual response, goals, and tolerance rather than male/female sex.
• Always use sterile reconstitution with bacteriostatic water and proper injection technique under guidance.
• Endocrine labs should be monitored frequently throughout therapy.

Safety & Precautions

MOTS-c is not approved for clinical use by the FDA and remains investigational. Its long-term safety and efficacy in humans are not established. MOTS-c appears on anti-doping prohibited lists and can have unknown risks. Always consult a healthcare professional before considering peptide therapy. (Wikipedia)

References
https://pubmed.ncbi.nlm.nih.gov/31378979/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/
https://peptidedosages.com/single-peptide-dosages/mots-c-10mg-vial-dosage-protocol/
https://www.americanmedicalwellness.com/mots-c-how-to-and-peptide-benefits/
https://en.wikipedia.org/wiki/MOTS-c